Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Duloxetine hydrochloride
Drug ID BADD_D00735
Description Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686.[A178741] Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder.[L6454] It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more.
Indications and Usage **Indicated** for: 1) Management of Major Depressive Disorder.[label] 2) Management of Generalized Anxiety Disorder.[label] 3) Management of diabetic peripheral neuropathy.[label] 4) Management of fibromyalgia.[label] 5) Management of chronic musculoskeletal pain.[label] 6) Management of osteoarthritis of the knee in adults.[L6364] 7) Management of chronic lower back pain in adults.[L6364] 8) Management of stress urinary incontinence in adult women.[L6367] **Off-label** uses include: 1) Management of chemotherapy-induced peripheral neuropathy.[A178603] 2) Management of stress urinary incontinence in adult men after prostatectomy until recovery is complete.[L6370]
Marketing Status approved
ATC Code N06AX21
DrugBank ID DB00476
KEGG ID D01179
MeSH ID D000068736
PubChem ID 60834
TTD Drug ID D01AXB
NDC Product Code 0110-3235; 43063-877; 43353-960; 50090-3205; 51991-746; 59651-280; 60687-745; 71335-0392; 71610-401; 0110-3270; 0110-9542; 0904-7043; 59651-282; 62128-0386; 73476-750; 51407-817; 63187-720; 82009-032; 65015-713; 25000-610; 33342-161; 43353-106; 51407-818; 57237-019; 63187-181; 63187-612; 68001-413; 57237-018; 61919-482; 63629-1990; 68788-8362; 71335-0165; 55111-859; 55745-0004; 59651-279; 68071-2711; 68788-7897; 71335-0509; 71610-402; 82009-029; 82009-030; 0110-9544; 49587-111; 73476-747; 25000-609; 60429-164; 60429-166; 60687-723; 61919-042; 68001-414; 68001-415; 82009-031; 0904-7044; 43353-025; 45865-815; 50090-2226; 55154-2341; 70518-0937; 0110-9543; 17337-0017; 51927-0059; 71554-015; 73476-746; 33342-162; 0002-3270; 51407-819; 60429-165; 63187-716; 63629-1991; 63629-2063; 68788-9301; 59286-1046; 68108-0705; 25000-608; 33342-160; 0002-3235; 43063-878; 51991-747; 51991-748; 60505-2995; 60687-734; 63187-666; 63187-702; 63187-735; 63629-1992; 63629-9187; 17337-0046; 73476-748; 0002-3240; 51991-750; 55154-2342; 57237-017; 63187-172; 68001-368; 71610-218; 0110-3240; 0110-9545; 14501-0005; 0904-7045; 51927-4999; 65862-463
UNII 9044SC542W
Synonyms Duloxetine Hydrochloride | Hydrochloride, Duloxetine | Duloxetine HCl | HCl, Duloxetine | LY 248686 | LY-248686 | LY248686 | Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987 | LY 227942 | LY-227942 | LY227942 | Duloxetine | N-methyl-3-(1-naphthalenyloxy)-3-(2-thiophene)propanamide | N-methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine | Duloxetine, (+)-isomer | Cymbalta
Chemical Information
Molecular Formula C18H20ClNOS
CAS Registry Number 136434-34-9
SMILES CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Suicidal ideation19.12.01.003--
Suicide attempt19.12.01.004--
Supraventricular tachycardia02.03.03.012--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Systolic hypertension24.08.02.007--Not Available
Tachycardia02.03.02.007--Not Available
Tension19.06.02.005--Not Available
Testicular pain21.13.01.005--
Thirst14.03.02.007; 08.01.09.021--Not Available
Throat tightness22.12.03.031; 19.01.02.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tremor17.01.06.002--
Trismus17.01.03.004; 15.05.04.004--
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urethral disorder20.07.01.002--Not Available
Urinary hesitation20.02.02.009--Not Available
Urinary incontinence20.02.02.010; 17.05.01.008--
Urinary retention20.02.02.011--
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection11.01.14.004; 20.08.02.001--
Urine flow decreased20.02.02.012--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Ventricular arrhythmia02.03.04.006--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.10.013--Not Available
Vital capacity decreased13.19.01.002--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
The 9th Page    First    Pre   9 10 11    Next   Last    Total 11 Pages